TGFB1 and non-small cell lung carcinoma: Therefore, therapeutic inhibition at multiple nodal points of the TGF-β signaling pathway represents a promising strategy for developing novel combinatorial regimens with immune checkpoint inhibitors in the treatment of non-small cell lung cancer.